Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Jeffrey R CurtisJ Lynn PalmerGeorge W ReedJeffrey GreenbergDimitrios A PappasLeslie R HarroldJoel M KremerPublished in: Arthritis care & research (2021)
Few patients receive triple therapy with MTX/SSZ/HCQ in the US. In the present study, drug persistence and clinical effectiveness outcomes were less favorable in triple therapy patients compared to TNFi/MTX therapy patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- combination therapy
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- rheumatoid arthritis
- emergency department
- type diabetes
- metabolic syndrome
- mesenchymal stem cells
- low dose
- patient reported outcomes
- bone marrow
- electronic health record